Institute for Neurodegenerative Diseases, Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, United States.
Institute for Neurodegenerative Diseases, Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, United States.
Neurobiol Dis. 2018 Jan;109(Pt B):191-200. doi: 10.1016/j.nbd.2017.03.014. Epub 2017 Mar 28.
The progressive nature of Alzheimer's disease (AD) is thought to occur, at least in part, by the self-replication and spreading of Aβ and Tau aggregates through a prion mechanism. Evidence now exists that structural variants of Aβ prions can propagate their distinct conformations through template-directed folding of naïve Aβ peptides. This notion implicates that the first self-propagating Aβ assembly to emerge in the brain dictates the conformation, anatomical spread and pace of subsequently formed deposits. It is hypothesized that a prion mechanism defines the molecular basis underlying the diverse clinicopathologic phenotypes observed across the spectrum of AD patients. Thus, distinct AD strains might require further sub-classification based on biochemical and structural characterization of aggregated Aβ. Here, we review the evidence for distinct, self-propagating Aβ strains, and discuss potential cellular mechanisms that might contribute to their manifestation. From this perspective, we also explore the implications of Aβ strains for current FDA-approved medical imaging probes and therapies for amyloid. Ultimately, the discovery of new molecular tools to differentiate Aβ strains and dissect the heterogeneity of AD may lead to the development of more informative diagnostics and strain-specific therapeutics.
阿尔茨海默病(AD)的进行性特征被认为至少部分是通过 Aβ 和 Tau 聚集物通过朊病毒机制的自我复制和传播发生的。现在有证据表明,Aβ 朊病毒的结构变体可以通过原始 Aβ 肽的模板指导折叠来传播其独特的构象。这一概念表明,在大脑中出现的第一个自我传播的 Aβ 组装决定了随后形成的沉积物的构象、解剖扩散和速度。据推测,朊病毒机制定义了 AD 患者谱系中观察到的不同临床病理表型的分子基础。因此,根据聚集的 Aβ 的生化和结构特征,可能需要对不同的 AD 菌株进行进一步分类。在这里,我们回顾了关于独特的、自我传播的 Aβ 菌株的证据,并讨论了可能有助于其表现的潜在细胞机制。从这个角度来看,我们还探讨了 Aβ 菌株对当前 FDA 批准的淀粉样蛋白成像探针和疗法的影响。最终,发现新的分子工具来区分 Aβ 菌株并剖析 AD 的异质性,可能会导致开发出更具信息量的诊断和针对菌株的治疗方法。